MAGiC Cardiac Ablation for Arrhythmias in Europe

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This feasibility study aims to collect safety and performance data on the MAGiC cardiac ablation system to support its marketing approval in Europe. The study will involve adult patients eligible for ablation procedures for various arrhythmias, including atrial fibrillation and ventricular tachycardia. Participants will undergo the MAGiC procedure and will be monitored for up to 12 months to assess outcomes and safety. Following European approval, the study will be expanded to include post-market clinical follow-up data.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adult (aged 18 or older at time of consent);
* Eligible for ablation procedures of an atrial or ventricular arrhythmia per European Heart Rhythm Association (EHRA) guidelines, lctrocardiographically documented within 12 months \[rior to enrollment;
* Able to be safely exposed to magnetic fields;
* Willing and capable to attend scheduled follow up visits at the study site for the study duration (up to 12 months)
* Willing and able to provide informed consent.

Exclusion Criteria:

* Unable to be safely exposed to magnetic fields due to Magnetic Resonance Imaging Unsafe device (implanted device or device that cannot be safely removed for the procedure)
* Unable to remain comfortable or hemodynamically stable in the supine position for an extended period of time
* Weight exceeding 200 kg (the weight limit of the table)
* Women of childbearing age who are pregnant or who plan to become pregnant within the course of their participation in the study. Must have a negative pregnancy test.
* Presence of intracardiac thrombus within 12 weeks prior to enrollment
* Where MAGiC would need to cross a prosthetic valve
* Use of MAGiC in the coronary arteries
* A history of sensitivity to foreign objects or extreme allergies
* Acute illness or active systemic infection
* Histological or anatomical abnormalities that may lead to post-operative complications including diminished resistance to infection
* Unable to receive heparin or an acceptable alternative to achieve adequate anticoagulation
* Acute myocardial infarct (within the previous 6 weeks)
* Recent cardiac surgery (within the previous 8 weeks)
* Unstable angina at the time of enrollment
* History of embolism (cerebrovascular accident, transient ischemic attack, systemic embolism) in the previous 30 days
* Previous cardiac ablation within the previous 30 days
* EP ablation within the previous 6 weeks.
* Life expectancy \<12 months per the physician opinion.
* Currently or in the 30 days prior to consent, participation in an interventional clinical trial
* Significant uncontrolled or unstable medical problems which, in the opinion of the Investigator, would preclude enrollment in and completion of the study (limitation on survival).
* Any reason or condition that, in the judgement of the investigator, makes the patient ineligible for the investigation.

Where it's running

• Rigshospitalet, University of Copenhagen
  Copenhagen, Denmark Recruiting
• Vilniaus universiteto ligoninė Santaros klinikos
  Vilnius, Lithuania Recruiting
• Erasmus Medical Center
  Rotterdam, Netherlands Not yet recruiting
• National Institute of Cardiology
  Warsaw, Poland Not yet recruiting

Study contacts

• Study coordinator: Betsy Lowry
• Email: betsy.lowry@stereotaxis.com
• Phone: 9737236613

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Can fluoroscopy plus TTE guidance improve leadless pacemaker placement accuracy

  This study tests whether using transthoracic echocardiography (TTE) during leadless pacemaker placement improves accuracy and safety compared with standard fluoroscopy.

  Recruiting Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) · Pittsburgh, Pennsylvania · NCT07908927

• Dual Energy ThermoCool SmartTouch SF Catheter with TRUPULSE Generator for Ventricular Arrhythmias

  This study tests a special catheter and generator setup to treat ventricular arrhythmias and checks that the procedure can be done safely following a specific workflow.

  Recruiting at 6 sites Biosense Webster, Inc. · Graz and 5 other locations · NCT07727057

• Volta AI software in real-world AF ablation

  A real-world observational study will test the latest Volta AF-Xplorer II AI software during atrial fibrillation ablation to see how safe and effective it is over 24 months.

  Recruiting Volta Medical · Marseille and 2 other locations · NCT07621055

• Pacing decisions guided by risk for pacing-induced heart muscle weakness

  This study tests a risk score to predict pacing-induced cardiomyopathy in adults getting heart rhythm devices, to tailor pacing choices.

  Recruiting at 2 sites Insel Gruppe AG, University Hospital Bern · Canberra, Australian Capital Territory and 12 other locations · NCT07276139

• Heart assessment to check repeat-stroke risk in people with atrial fibrillation

  This project will test whether detailed heart examinations can find which people with atrial fibrillation who just had an ischemic stroke are at high risk of having another stroke.

  Recruiting Insel Gruppe AG, University Hospital Bern · Bern · NCT06954610

• Sensor-guided exercise program for people with atrial fibrillation

  This program will test whether a Fitbit-based, personalized exercise plan can reduce symptoms and episode burden in people with paroxysmal atrial fibrillation.

  Recruiting Icahn School of Medicine at Mount Sinai · New York, New York · NCT06938412

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.